Skip to main content
ZELIRA THERAPEUTICS LIMITED logo

ZELIRA THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · ZLD ISIN · AU000000ZLD1 ASX Manufacturing
Open in API
Filings indexed 974 across all filing types
Latest filing 2025-09-25 Governance Information
Country AU Australia
Listing ASX ZLD

About ZELIRA THERAPEUTICS LIMITED

https://zeliratx.com/

Zelira Therapeutics Limited is a biopharmaceutical company focused on the research, development, and commercialization of clinically validated cannabinoid-based medicines. The company utilizes a data-driven approach to develop therapeutic products targeting conditions such as insomnia, chronic pain, and autism. Its portfolio includes Zenivol, a clinically validated treatment for insomnia, and the HOPE range of products designed for patients with autism. Zelira emphasizes a clinical trial-led strategy to establish the safety and efficacy of its formulations, aiming to provide healthcare professionals and patients with evidence-based cannabinoid treatments. The company also explores dermatological applications and maintains a pipeline of proprietary formulations undergoing rigorous scientific evaluation to address unmet medical needs in global markets.

Recent filings

Filing Released Lang Actions
Appendix 4G 20 pages 641.5KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a detailed governance disclosure document related to the corporate governance statement of Zelira Therapeutics Limited for the financial year ended 30 June 2025. The document serves as a key to where governance disclosures can be found and confirms compliance with ASX Corporate Governance Council recommendations. It is not the corporate governance statement itself but a supplementary disclosure required to be lodged with the ASX alongside the annual report. The document does not contain financial statements or management discussion but focuses on governance disclosures and compliance verification. This matches the description of Governance Information (CGR) filings, which detail internal rules, board structure, and governance practices. The document length (15,000 characters) and content confirm it is a full governance disclosure, not a brief announcement or certification. Therefore, the correct classification is CGR with high confidence.
2025-09-25 English
AGM Date and Closing Date for Director Nominations 3 pages 1.7MB
AGM Information Classification · 95% confidence The document is an ASX announcement dated 23 September 2025 regarding the date of the Annual General Meeting (AGM) and the closing date for director nominations. It does not contain financial statements, detailed financial performance, or management discussion of results. Instead, it provides logistical information about the AGM and director nominations, which is typical of an announcement related to the AGM but not the AGM materials or report itself. The document is relatively short (5254 characters) and serves as a notice rather than a full report or presentation. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or about the AGM, including notices and announcements related to the AGM.
2025-09-22 English
Director Loans 4 pages 1.6MB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 16 September 2025 regarding unsecured loan notes provided by company directors to Zelira Therapeutics Ltd. It details the terms of the loan notes, including amounts, interest, maturity, and conversion terms subject to shareholder approval at the upcoming 2025 Annual General Meeting. The document focuses on financing activities, specifically the issuance of convertible loan notes and the use of funds for working capital. There is no detailed financial report, earnings data, or management discussion of financial results. The content is clearly an update on capital raising and financing arrangements rather than a full financial report or regulatory filing. Therefore, the document best fits the category of Capital/Financing Update (CAP). The document length (8007 characters) supports it being a substantive announcement rather than a brief notice or report publication announcement.
2025-09-15 English
Preliminary Final Report 13 pages 548.9KB
Annual Report Classification · 95% confidence The document is titled 'APPENDIX 4E Preliminary Final Report FOR THE YEAR ENDED 30 JUNE 2025' and references the ASX listing rule 4.3A, which is a standard for preliminary final reports in Australia. It contains detailed financial data including consolidated statements of profit or loss, financial position, cash flow, and notes to the financial statements. The document covers a full fiscal year (12 months ended 30 June 2025) and includes comprehensive financial performance and position information. It also discusses operational highlights, clinical trial progress, funding, and corporate developments. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a full financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K equivalent) for the Australian market, often filed as Appendix 4E preliminary final report. Hence, the correct classification is '10-K'. FY 2025
2025-08-28 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 1.5MB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'Quarterly Activities Report for Q4 FY2025' and includes detailed operational and financial information for the quarter ended 30 June 2025. It contains a financial snapshot with cash flow statements, operational highlights, updates on clinical studies, funding activities, and strategic outlook. The presence of Appendix 4C (quarterly cash flow report) confirms it is a quarterly report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. It includes substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q4 2025
2025-07-29 English
Zelira Therapeutics Secures R&D Loan Facility 3 pages 1.7MB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 24 July 2025 about Zelira Therapeutics securing a non-dilutive R&D loan facility. It details the loan terms, purpose, and comments from the CEO. The content focuses on financing activities related to R&D tax incentives and working capital. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document is a corporate announcement about a financing arrangement rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (6884 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2025-07-23 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.